PRDM2 Target
Lung Cancer
Key Facts
About ARIZ Precision Medicine
ARIZ Precision Medicine is a private, preclinical-stage biotech founded in 2018 and headquartered in Phoenix, Arizona (with operations noted in Davis, California). The company is developing a precision oncology platform that targets specific PRDM family genes using siRNA therapeutics delivered via a targeted nanotechnology system. With a recently granted broad US patent, a key collaboration with the UK's Nucleic Acid Therapy Accelerator (NATA), and a recent $110,000 angel investment, ARIZ is advancing a multi-indication pipeline focused on major solid and hematologic cancers. Its leadership team combines deep expertise in oncology, RNAi, drug development, and business, including the inventor of pegylation and a Herceptin co-inventor.
View full company profileAbout ARIZ Precision Medicine
ARIZ Precision Medicine is a private, preclinical-stage biotech founded in 2018 and headquartered in Phoenix, Arizona (with operations noted in Davis, California). The company is developing a precision oncology platform that targets specific PRDM family genes using siRNA therapeutics delivered via a targeted nanotechnology system. With a recently granted broad US patent, a key collaboration with the UK's Nucleic Acid Therapy Accelerator (NATA), and a recent $110,000 angel investment, ARIZ is advancing a multi-indication pipeline focused on major solid and hematologic cancers. Its leadership team combines deep expertise in oncology, RNAi, drug development, and business, including the inventor of pegylation and a Herceptin co-inventor.
View full company profileAbout ARIZ Precision Medicine
ARIZ Precision Medicine is a private, preclinical-stage biotech founded in 2018 and headquartered in Phoenix, Arizona (with operations noted in Davis, California). The company is developing a precision oncology platform that targets specific PRDM family genes using siRNA therapeutics delivered via a targeted nanotechnology system. With a recently granted broad US patent, a key collaboration with the UK's Nucleic Acid Therapy Accelerator (NATA), and a recent $110,000 angel investment, ARIZ is advancing a multi-indication pipeline focused on major solid and hematologic cancers. Its leadership team combines deep expertise in oncology, RNAi, drug development, and business, including the inventor of pegylation and a Herceptin co-inventor.
View full company profileTherapeutic Areas
Other Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| OncoStrong™ | Lamark Biotech | Preclinical |
| 15dPMJ2 | Claradele Pharmaceuticals | Research |
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |
| Oncology Digital Biomarkers | Imvaria | Development |
| Aerosolized Platinum Nanoparticles | HylaPharm | Pre-clinical |
| ENV105 | Kairos Pharma | Phase 1 |
| AI for Lung Cancer | Invenio Imaging | Research |
| Liposome Program | NanoTech Pharma | Preclinical/Phase 1/2 |
| Dendritic Cell Vaccine | MegaNano BioTech | Pre-clinical |
| AI Biomarkers for Lung Cancer | BioAI Health | Unknown |
| ZEN-3694 | Zenith Epigenetics | Proof-of-Concept |
| TEC-001 + Keytruda | Teclison | Phase 2 |